TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone561-961-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.10 million
Profitability
Miscellaneous
Employees241
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) posted its earnings results on Tuesday, August, 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. The company had revenue of $6.08 million for the quarter, compared to analysts' expectations of $5.12 million. TherapeuticsMD had a negative return on equity of 212.57% and a negative net margin of 913.07%. The firm's quarterly revenue was up 60.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.15) EPS. View TherapeuticsMD's Earnings History.
When is TherapeuticsMD's next earnings date?
What guidance has TherapeuticsMD issued on next quarter's earnings?
TherapeuticsMD issued an update on its FY 2019 earnings guidance on Wednesday, October, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $29.45-34.2 million, compared to the consensus revenue estimate of $31.45 million.
What price target have analysts set for TXMD?
8 equities research analysts have issued 1-year price targets for TherapeuticsMD's shares. Their forecasts range from $3.00 to $20.00. On average, they expect TherapeuticsMD's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 166.0% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.
What is the consensus analysts' recommendation for TherapeuticsMD?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.
What are Wall Street analysts saying about TherapeuticsMD stock?
Here are some recent quotes from research analysts about TherapeuticsMD stock:
- 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (10/19/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019)
Has TherapeuticsMD been receiving favorable news coverage?
Press coverage about TXMD stock has been trending somewhat negative recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. TherapeuticsMD earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for TherapeuticsMD.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Emergent Biosolutions (EBS), Genmab A/S (GMAB), HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE) and Arena Pharmaceuticals (ARNA).
What other stocks do shareholders of TherapeuticsMD own?
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
- Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
- Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Moors & Cabot Inc. (0.02%), Nisa Investment Advisors LLC (0.01%) and CIBC Private Wealth Group LLC (0.00%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.
Which major investors are buying TherapeuticsMD stock?
TXMD stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Moors & Cabot Inc. and CIBC Private Wealth Group LLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $3.76.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $906.99 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.
What is TherapeuticsMD's official website?
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
